Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data

Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed data

  • August 5, 2026

Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is already on the hunt for bolt-on deals.

Leave A Comment

Fields (*) Mark are Required